Since then, in last 3 years we have built a robust pipeline of almost 35 products, now at various stages from, being registered to just signed for development. Although the major focus is on prescription products, we also have a portfolio of some interesting over-the-counter products filed which provides us quicker access to the market and a scope to build a brand around Maypharm in Brazil.
Sameer Kolhe, President, Maypharm Life Sciences | 13/02/2022
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy